Aeterna Zentaris, Inc. (USA) (NASDAQ:AEZS)

phase ill study looks promising. way oversold

I am a money manager and hold a majority of the portfilio in Aeterna Zentaris. The company is a great small cap speculative play. They have great fundamentals, but if Perifosine gets approval and the other drugs in pipeline gets approval, it will be the next large cap biotech company.

Its going to take off with KERX!

Nice pipeline, will do good if anything comes of the drugs.

Soon Every One Will Fly

New drugs in Phase III will feed the profits pipeline well into the next decade for superior performance over their rivals.

Aeterna is a company that will skyrocket. Not hyping! Just look at the facts. AEterna is awaiting several key developments:

1.Bone Marrow Cancer: Developing perifosine, the first-in-class oral AKT inhibitor. A Phase III study, the last stage before commercialization, is currently being conducted in the United States for myeloma, a form of bone marrow cancer. Perifosine has been granted a fast-track designation and orphan-drug designation by the FDA. Plan to update development and registration strategy for ex-North American territories in 2011.

2.Colon cancer: Keryx is about to start a Phase III study with this same compound as Perifosine in metastatic colon cancer.
3.Endometrial cancer and Ovarian cancer: AEZS-108. Conducting a Phase II study in Europe for endometrial cancer and ovarian cancer. They expect to disclose the final results by year end 2010.

4.Bladder cancer, pancreatic cancer and prostate cancer: AEterna is also looking to possibly conduct other clinical studies in bladder cancer, and pancreatic cancer and refractory prostate cancer mid-to-end 2010.

5.In vitro fertilization: In endocrinology, AEterna has already marketed a product for in vitro fertilization under the brand name Cetrotide(c). It is being marketed worldwide by Merck Serono, except in Japan, where it’s marketed by Nippon Kayaku and Shionogi. Update on sales figures could come in 2010.

6.Growth hormone deficiency: The lead endocrinology compound in late-stage development is AEZS-130, which is in Phase III as a diagnostic test for growth hormone deficiency (GHD) could receive an update soon. They also have an orphan-drug designation for this drug in the United States. Currently in discussions with the FDA in order to find the best way to finalize this study for AEZS-130 and file for an approval at the end of 2010.

7.Children diagnostic test: AEterna is also aiming for diagnostic use of AEZS-130 in children. The unique selling point of this project is that this will be the first oral diagnostic test, expect an update in 2010 to early 2011.

8.Treat cachexia: AEZS-130 has shown to stimulate appetite and therefore could be used to treat cachexia, a condition which results in a severe reduction of muscle mass and weight loss in patients suffering from conditions such as chronic obstructive pulmonary disease, AIDS and certain cancers. Potential update in 2010.

9.At the pre-clinical development stage, AEterna has some very unique molecules which are dual inhibitors of PI3K and Erk, two hot targets in oncology at present, and also a selective Erk inhibitor.

10.Some of these early-stage projects as well as the more advanced ones will be the object of presentations at major conferences throughout 2010, such as the upcoming American Society of Clinical Oncology, ASCO, and American Association of Cancer Research meetings.
11.AEterna has stated publicly that they are actively looking for partners to market their treatments outside of North America even as they await U.S. regulatory approvals. News could come at any time.
Keryx may have the North America rights to Perefosine but Aeterna gets royalty payments averaging 10% and the rest of the world to itself. Aeterna will be a cash cow. So load up on the shares and watch it keep going up and up!!!!!!

They have three drugs in phase 3, 3 in phase 2 and 3 in phase 1. Persifone will be FDA approved within a year. This stock will follow in Kerx footsteps untill after Persifone is approved. AEZS is better long term unless Kerx buys them out.

Aezs is going up .. it has more medicatios in all phases of the FDA. kerx is riding on it's coat tail.

Bio Beautiful

Expecting positive phase 3 results for Cetrorelix sometime this Q

Short term: This stock is probable to Underperform. The Company provided updated guidance for the 2007 total expected burn in a range of $25-$27 million.

Long term: This will be a hot stock to own. Potential for base case peak annual sales of over $500 million in the United States market alone; lower sales could reach $200 million.

this company has outstanding leadership along with promising products in various phases. It also MAKES an income and has very good cash balance.

This is a sure thing, chech this out:

AETERNA ZENTARIS

swap some letters around...

ZANIEST EARN RATE

undervalued with a strong pipeline.

Uhhhh............ it will just do bad. :) --A Scientist

short term recovery

Small bio-tech with several drugs in pipeline ready for approval.

Undervalued.
2 Drugs on Market
2 in phase 3
5 in Phase 2

70 million in Cash